Knights of Columbus Asset Advisors LLC Has $981,000 Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

Knights of Columbus Asset Advisors LLC cut its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.5% during the second quarter, HoldingsChannel reports. The fund owned 19,268 shares of the company’s stock after selling 489 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Mirum Pharmaceuticals were worth $981,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of MIRM. GAMMA Investing LLC increased its stake in shares of Mirum Pharmaceuticals by 4,555.0% in the first quarter. GAMMA Investing LLC now owns 5,586 shares of the company’s stock worth $252,000 after acquiring an additional 5,466 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Mirum Pharmaceuticals by 4.4% in the 1st quarter. Rhumbline Advisers now owns 55,434 shares of the company’s stock valued at $2,497,000 after purchasing an additional 2,321 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Mirum Pharmaceuticals by 174.9% in the 1st quarter. SG Americas Securities LLC now owns 19,182 shares of the company’s stock valued at $864,000 after purchasing an additional 12,204 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Mirum Pharmaceuticals by 2.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company’s stock worth $752,000 after purchasing an additional 339 shares in the last quarter. Finally, Palumbo Wealth Management LLC bought a new stake in Mirum Pharmaceuticals in the first quarter worth $242,000.

Mirum Pharmaceuticals Stock Up 1.7%

MIRM stock opened at $73.74 on Wednesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.13 and a quick ratio of 2.97. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $78.10. The company has a 50-day moving average of $69.44 and a two-hundred day moving average of $54.22. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of -60.94 and a beta of 0.81.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The company had revenue of $127.79 million during the quarter, compared to analysts’ expectations of $107.91 million. During the same period in the prior year, the company earned ($0.52) earnings per share. The business’s quarterly revenue was up 64.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Insider Activity

In related news, Director Laura Brege sold 17,000 shares of the stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $74.40, for a total value of $1,264,800.00. Following the completion of the sale, the director owned 15,703 shares in the company, valued at approximately $1,168,303.20. This trade represents a 51.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Eric Bjerkholt sold 9,578 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $76.01, for a total transaction of $728,023.78. Following the completion of the sale, the chief financial officer owned 39,945 shares of the company’s stock, valued at approximately $3,036,219.45. The trade was a 19.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,578 shares of company stock valued at $7,262,824 over the last three months. 22.87% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MIRM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Saturday, September 27th. JMP Securities set a $81.00 price objective on shares of Mirum Pharmaceuticals and gave the stock a “market outperform” rating in a report on Thursday, August 7th. Evercore ISI upped their price objective on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. JPMorgan Chase & Co. upped their price objective on shares of Mirum Pharmaceuticals from $53.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $76.50.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.